Liver Cancer Therapeutics Market to Hit USD 15.69 Billion by 2032, growing at a CAGR of 19.21% - SNS Insider
Liver Cancer Therapeutics Market Growth is Driven by Advancements in Precision Medicine, Immunotherapy and Growing Global Incidence.Pune, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Liver Cancer Therapeutics ...
GlobalData on MSN3d
FDA grants fast track status to Rznomics’ RZ-001 for HCC
The US FDA has granted fast track designation to Rznomics' RZ-001 for the treatment of hepatocellular carcinoma (HCC).
Tempest Therapeutics granted FTD from FDA for amezalpat
Tempest Therapeutics (TPST) announced that the U.S. Food and Drug Administration, FDA, has granted Fast Track Designation, FTD, to amezalpat, ...
EurekAlert!3d
Unraveling the role of the Wnt pathway in hepatocellular carcinoma: From molecular mechanisms to therapeutic implications
Hepatocellular carcinoma (HCC) is one of the deadliest malignant tumors in the world, and its incidence and mortality have ...
Monthly Prescribing Reference8d
Amezalpat Gets Fast Track Status for Hepatocellular Carcinoma
Amezalpat is an investigational oral, small molecule, selective peroxisome proliferator-activated receptor-alpha antagonist.
Science Daily10d
Candidate genes in canine hepatocellular carcinoma for molecular targeted therapy
Unresectable canine hepatocellular carcinoma (HCC) has limited nonsurgical treatment options. Sorafenib is a targeted therapy for unresectable canine HCC. However, there are limited reports on the ...